Why Molecular Partners AG’s (MOLN) Stock Is Down 5.02%
As of Wednesday, September 02, Molecular Partners AG’s MOLN share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Commentary & Analysis
Why Molecular Partners AG’s (MOLN) Stock Is Down 6.13%
As of Tuesday, August 25, Molecular Partners AG’s MOLN share price has dipped by 6.13%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Molecular Partners AG’s (MOLN) Stock Is Up 8.14%
As of Monday, August 03, Molecular Partners AG’s MOLN share price has surged by 8.14%, which has investors questioning if this is right time to sell.Michael Rose
Why Molecular Partners AG’s (MOLN) Stock Is Down 8.53%
As of Monday, June 08, Molecular Partners AG’s MOLN share price has dipped by 8.53%, which has investors questioning if this is right time to buy.Michael Rose
Why Molecular Partners AG’s (MOLN) Stock Is Up 7.89%
As of Friday, May 22, Molecular Partners AG’s MOLN share price has surged by 7.89%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $159.8 | $288.9 | 25% |
|
| Shares Out (Mil) | 47.4 | 54.0 | 46% |
|
| Institutional Ownership | 68.1% | 93.1% | 42% |
|
| Float (Mil) | 20.7 | 41.4 | 29% |
|
| Beta | 0.68 | 0.94 | 40% |
|
| Avg Daily Volume (000s) | 2 | 480 | 9% |
|
| Price Change (52-week) |
3.0% | 59.9% | 49% |
|
| Growth | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (1.8%) | (10.1%) | 37% |
|
| EPS (5yr) | 6.0% | 15.9% | 40 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.4%) | (15.6%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 3 | 3 | |
| Current EPS | ($0.418) | ($1.367) | ($0.167) | |
| Month Ago EPS | ($0.437) | ($0.802) | $0.284 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.418) | ($1.262) | $0.284 | |
| Year/Year Chg | (4.6%) | (34.5%) | (36.8%) | |
| Financials | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($63) | ($43) | 14% |
|
| EPS (TTM) | ($1.682) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($57) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($18) | $2 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $90 | $190 | 20% |
|
| Valuation | MOLN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.15 | 2.84 | 53% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (50.7%) | (47.7%) | 11% |
|
| ROE | (61.3%) | (55.0%) | 13% |
|
| Liabilities to Assets | 22.7% | 29.6% | 15% |
|
| F-Score | 1 | 3 | 1% |
|
Molecular Partners AG did not pass any screens on 9/2/2026.
